Last reviewed · How we verify
D-Mannitol
D-Mannitol is an osmotic agent that draws fluid into the intracellular space to reduce intracranial pressure and improve cellular hydration.
D-Mannitol is an osmotic agent that draws fluid into the intracellular space to reduce intracranial pressure and improve cellular hydration. Used for Investigational neuroprotective indication (specific indication not publicly disclosed).
At a glance
| Generic name | D-Mannitol |
|---|---|
| Sponsor | Thiogenesis Therapeutics, Inc. |
| Drug class | Osmotic diuretic |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
D-Mannitol functions as an osmotic diuretic by creating an osmotic gradient that pulls water from tissues into the vascular space, thereby reducing intracranial pressure and cerebral edema. It may also have cytoprotective properties by improving cellular hydration and reducing oxidative stress. In the context of Thiogenesis Therapeutics' development, it is being investigated for potential neuroprotective applications.
Approved indications
- Investigational neuroprotective indication (specific indication not publicly disclosed)
Common side effects
- Dehydration
- Electrolyte imbalance
- Renal dysfunction
- Hyperglycemia
Key clinical trials
- Effect of Infusion Warming on Mannitol Infusion Pain in Patients With Acute Ocular Hypertension (NA)
- Dose-dependent FODMAP Reintroduction in IBS (NA)
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) (PHASE2)
- Comparison of Changes in Intra-myocardial Amino Acids During Use of Calafiore and Modified Del Nido Cardioplegia
- Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia. (PHASE2)
- Mannitol Versus Nitroglycerin for Kidney Injury Prevention in Robotic-assisted Radical Prostatectomy or Cystectomy (NA)
- Does Caffeine Facilitate Human Reward Learning Behaviors? (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- D-Mannitol CI brief — competitive landscape report
- D-Mannitol updates RSS · CI watch RSS
- Thiogenesis Therapeutics, Inc. portfolio CI